Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown DA, Mor G. Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells. Mol Cancer Ther. 2011 June 15. [Epub ahead of print] [ Abstract ]
Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, Mor G, Saif MW, Husband AJ, Brown DM, Tytler Em. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs. 2011 June 9. [Epub ahead of print] [ Abstract ]
Kelly MG, Mor G, Husband A, O'Malley DM, Baker L, Azodi M, Schwartz PE, Rutherford TJ. Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers. Int J Gynecol Cancer. 2011 March 15. [Epub ahead of print] [ Abstract ]
Howes JB, de Souza PL, West L, Huang LJ, Howes LG. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. BMC Clin Pharmacol. 2011 Feb 3;11:1. [ Abstract ]
de Souza PL, Russell PJ, Kearsley JH, Howes LG. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev. 2010 Sep;68(9):542-55. [ Abstract ]
Aguero MF, Venero M, Brown DM, Smulson ME and Espinoza LA. Phenoxodiol inhibits growth of metastatic prostate cancer cells. The Prostate. 2010 Aug;70(11):1211-1221. [ Abstract ]
De Luca T, Morré DM, Morré DJ. Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. J Cell Biochem. 2010 Aug 15;110(6):1504-11. [ Abstract ]
Georgaki S, Skopeliti M, Tsiatas M, Nicolaou KA, Ioannou K, Husband A, Bamias A, Dimopoulos MA, Constantinou AI, Tsitsilonis OE. Phenoxodiol, an anticancer isoflavone, induces immunomodulatory effects in vitro and in vivo. J Cell Mol Med. 2009 Sep;13(9B):3929-38. [ Abstract ]
Herst PM, Davis JE, Neeson P, Berridge MV, Ritchie DS. The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells. Haematologica. 2009 Jul;94(7):928-34. [ Full article ]
Alvero AB, Montagna MK, Chen R, Kim KH, Kyungjin K, Visintin I, Fu HH, Brown D, Mor G. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer. 2009 Jul;115(14):3204-16. [ Full article ]
Morré DJ, McClain N, Wu LY, Kelly G, Morré DM. Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin. Mol Biotechnol. 2009 May;42(1):100-9. [ Abstract ]
Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investig Drugs. 2009 Apr;18(4):469-79. [ Abstract ]
Silasi DA, Alvero AB, Rutherford TJ, Brown D, Mor G. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother. 2009 Apr;10(6):1059-67. [ Abstract ]
McPherson RA, Galettis PT, de Souza PL. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. Br J Cancer. 2009 Feb 24;100(4):649-55. [ Full article ]
De Luca T, Bosneaga E, Morré DM, Morré DJ. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol. Biofactors. 2009;34(3):253-60. [ Abstract ]
Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, Mor G. Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncol. 2008 Aug;4(4):475-482. [ Abstract ]
Mor G, Montagna MK, Alvero AB. Modulation of apoptosis to reverse chemoresistance. Methods Mol Biol. 2008;414:1-12. [ Abstract ]
Brown D, Heaton A, Husband A. Idronoxil. Drugs Fut. 2008;33(10):844-860. [ Abstract ]
Alvero AB, Rossi P, Brown D, Leiser A, Kelly M, Rutherford T, Husband AJ, Mor G. Phenoxodiol – a chemosensitizer in the midst of cancer chemoresistance. US Oncology. 2008;4:39-41.
Herst PM, Petersen T, Jerram P, Baty J, Berridge MV. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumor cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3;74(11):1587-95. [ Abstract ]
Klein R, Brown D, Turnley AM. Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model. BMC Neurosci. 2007 Aug 1;8:61. [ Full article ]
Yagiz K, Wu LY, Kuntz CP, Morré DJ, Morré DM. Mouse embryonic fibroblast cells from transgenic mice overexpressing tNOX exhibit an altered growth and drug response phenotype. J Cell Biochem. 2007 May 15;101(2):295-306. [ Abstract ]
Alvero AB, Brown D, Montagna M, Matthews M, Mor G. Phenoxodiol-topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. Cancer Biol Ther. 2007 Apr;6(4):612-7. [ Full article ]
Kluger HM, McCarthy MM, Alvero AB, Sznol M, Camp RL, Rimm DL, Mor G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med. 2007 Jan 26;5:6. [ Full article ]
Morré DJ, Chueh PJ, Yagiz K, Balicki A, Kim C, Morré DM. ECTO-NOX target for the anticancer isoflavene phenoxodiol. Oncol Res. 2007;16(7):299-312. [ Abstract ]
Sabbadini RA. Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer. 2006 Nov 6;95(9):1131-5. [ Full article ]
Yu F, Watts RN, Zhang XD, Borrow JM, Hersey P. Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells. Anticancer Drugs. 2006 Nov;17(10):1151-61. [ Abstract ]
Yagiz K, Morré DJ, Morré DM. Transgenic mouse line overexpressing the cancer-specific tNOX protein has an enhanced growth and acquired drug-response phenotype. J Nutr Biochem. 2006 Nov;17(11):750-9. [ Abstract ]
Shen J, White M, Husband AJ, Hambly BD, Bao S. Phytoestrogen derivatives differentially inhibit arterial neointimal proliferation in a mouse model. Eur J Pharmacol. 2006 Oct 24;548(1-3):123-8. [ Abstract ]
de Souza PL, Liauw W, Links M, Pirabhahar S, Kelly G, Howes LG. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemother Pharmacol. 2006 Oct;58(4):427-33. [ Abstract ]
Mor G, Fu HH, Alvero AB. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Investig Drugs. 2006 Jun;7(6):542-8. [ Abstract ]
Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D, Vadas MA. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumor effects. Int J Cancer. 2006 May 15;118(10):2412-20. [ Abstract ]
Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol. 2006 May;17(5):860-5. [ Full article ]
Davies SL, Bozzo J. Spotlight on tNOX: a tumor-selective target for cancer therapies. Drug News Perspect. 2006 May;19(4):223-5. [ Abstract ]
Choueiri TK, Wesolowski R, Mekhail TM. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep. 2006 Mar;8(2):104-107. [ Abstract ]
Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T, Mor G. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer. 2006 Feb 1;106(3):599-608. [ Full article ]
Axanova L, Morré DJ, Morré DM. Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors. Cancer Lett. 2005 Jul 8;225(1):35-40. [ Abstract ]
Brown DM, Kelly GE, Husband AJ. Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol Biotechnol. 2005 Jul;30(3):253-270. [ Abstract ]
Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 2005 Apr 15;65(8):3364-73. [ Full article ]
De Luca T, Morré DM, Zhao H, Morré DJ. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. BioFactors. 2005;25(1-4):43-60. [ Abstract ]
Chin-Dusting JP, Boak L, Husband A, Nestel PJ. The isoflavone metabolite dehydroequol produces vasodilatation in human resistance arteries via a nitric oxide-dependent mechanism. Atherosclerosis. 2004 Sep;176(1):45-8. [ Abstract ]
Wilkinson E. Phenoxodiol offers hope for ovarian cancer. Lancet Oncol. 2004 Apr;5(4):201. [ Abstract ]
Straszewski-Chavez SL, Abrahams VM, Funai EF, Mor G. X-linked inhibitor of apoptosis (XIAP) confers human trophoblast cell resistance to Fas-mediated apoptosis. Mol Hum Reprod. 2004 Jan;10(1):33-41. [ Full article ]
Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, Garg M, Kamsteeg M, Rutherford T, Mor G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res. 2004;14(11-12):567-78. [ Abstract ]
Constantinou AI, Mehta R, Husband A. Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. Eur J Cancer. 2003 May;39(7):1012-8. [ Abstract ]
Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G. Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003 May 1;22(17):2611-20. [ Abstract ]
Kelly GE, Husband A.J. Flavonoid compounds in prevention and treatment of prostate cancer. Methods Mol Med. 2003;81:377-94. [ Full article ]
Constantinou AI, Husband A. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res. 2002 Sep-Oct;22(5):2581-5. [ Abstract ]
Alvero AB, Montagna MK, Holmberg JC, Brown DM, Mor G. Depression of mitochondrial bioenergetics is a potent death stimulus in the ovarian cancer stem cells. AACR Annual Meeting, Apr 2011. [Poster]
Alvero AB, Montagna MK, Holmberg JC, Brown D, Mor G. Targeting the mitochondria activates two independent pathways leading to caspase-independent cell death in ovarian cancer stem cells. World Congress on Targeting Mitochondria, Nov 2010. [ Press release ]
Gibney G, Elfiky A, Bussom S, Hoimes CJ, Burns A, McDonough JA, Rowen E, Cheng YC, Kelly WK. A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes. ASCO Annual Meeting, Jun 2010. [ Abstract ]
Saif M, Brown D, Husband A. Pre-clinical toxicology of triphendiol. AACR Annual Meeting, Apr 2009. [ Abstract ]
Mor G, Alvero A, Montagna M, Brown D, Husband A. NV-128, a novel isoflavone derivative, targets the mTOR pathway and induces cell death in epithelial ovarian cancer stem cells. AACR Annual Meeting, Apr 2009. [ Abstract ]
Elfiky A, Clark J, Rowen E, Chao H, Delvy M, Israel G, Kelly W. Phase II study of oral phenoxodiol in patients with castrate and non-castrate prostate cancer. ASCO Genitourinary Cancers Symposium, Feb 2009. [ Abstract ]
Wang X, Kim K, Alvero A, Mor G, Thompson J, Brown D, Tytler E. Triphendiol (NV-196) induces apoptosis and sensitizes pancreatic cancer cells to gemcitabine. AACR Annual Meeting, Apr 2008. [ Abstract ]
Mor M, Montagna M, Kim K, Brown D, Alvero A. Activation of caspase-independent programmed cell death overcomes apoptosis resistance in ovarian cancer cells. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Oct 2007. [ Abstract ]
McKernan R, Tytler E, McDougall F, Whiting A, Husband A, Brown D. Development of NV-196 as a gemcitabine chemo-sensitizer for treatment of pancreatic adenocarcinoma and cholangiocarcinoma. Discovery Science and Biotechnology Meeting, Jul-Aug 2007.
Alvero A, Montagna M, Kim KH, Mor G. Autophagy precedes caspase-independent cell death in chemo-resistant ovarian cancer cells. AACR Annual Meeting, Apr 2007. [ Abstract ]
Mahoney S, Brown D, Kelly G, Millward M, Dharmarajan A. The effects of phenoxodiol on the ß-catenin pathway in prostate cancer. AACR Annual Meeting, Apr 2007. [ Abstract ]
Morre DJ, Hostetler B, Morre DM, Kelly G. tNOX as a serum marker for detection and estimation of tumor burden in prostate cancer. AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Sep 2006. [ Abstract ]
Kluger HM, McCarthy M, Alvero A, Divito K, Camp R, Rimm D, Mor G. XIAP is highly expressed in melanoma and is associated with chemotherapy resistance. ASCO Annual Meeting, Jun 2006. [ Abstract ]
Mahoney S, Hisheh S, Brown D, Kelly G, Millward M, Dharmarajan A. The effects of phenoxodiol on apoptotic pathways in prostate cancer cells. AACR Annual Meeting, Apr 2006. [ Abstract ]
Kelly MG, Mor G, Goss G, Kelly G, Quinn M, O'Malley DM, Baker L, McAlpine JN, Azodi M, Schwartz PE, Rutherford TJ. Phase II evaluation of Phenoxodiol in combination with cisplatin or paclitaxel in women with a history of platinum/taxane refractory/resistant epithelial ovarian,fallopian tube or primary peritoneal cancers. Annual Meeting on Women's Cancer, Mar 2006; Abstr. No. 909.
Goss G, Quinn M, Rutherford T, Kelly M, Kelly G. A randomised phase II study of Phenoxodiol with platinum or taxane chemotherapy in chemoresistant epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. MOGA Annual Scientific Meeting, Aug 2005.
Cabot MC, Yu JY, Kelly GE, Brown DM, Lucas KM, Tanabe K, Allen JD. Phenoxodiol, a synthetic analog of genistein, generates ceramide and is equipotent in wild-type and multidrug-resistant human tumor cells. ASCO Annual Meeting, May 2005. [ Abstract ]
Alvero AB, Rutherford T, Mor G. Phenoxodiol-induced apoptosis depends on the simultaneous activation of the mitochondria and degradation of XIAP. AACR Annual Meeting, Apr 2005. [ Abstract ]
Davies R, Tulloch A, Frydenberg M, Kelly G. Final results of phase Ib/IIa study of Phenoxodiol in hormone-refractory prostate cancer. AACR Basic, Translational and Clinical Advances in Prostate Cancer Conference, Nov 2004.
Rutherford T, O'Malley D, Makkenchery A, Baker L, Azodi M, Schwartz P, Mor G. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to ≥ second line chemotherapy. AACR Annual Meeting, Mar 2004. [ Abstract ]
Davies R, Frydenberg M, Tulloch A, Kelly G. Interim results of phase Ib/IIa study of oral Phenoxodiol in patients with late-stage, hormone-refractory prostate cancer. AACR Annual Meeting, Mar 2004.
Aguero M, Facchinetti MM, Senderowicz AM. Phenoxodiol, a novel isoflavone, promotes G1/S arrest by upregulation of p21 in head and neck squamous and salivary gland carcinoma cell lines. AACR Annual Meeting, Mar 2004. [ Abstract ]
Mor G, Chen W, Sapi E, O'Malley D, Garg M, Rutherford T. Phenoxodiol a chemosensitizer in taxotere-resistant ovarian cancer cells. AACR Annual Meeting, Mar 2004. [ Abstract ]
Rutherford T, O'Malley D, Makkenchery A, Baker L, Azodi M, Chambers S, Schwartz P, Mor G. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that is resistant to second line chemotherapy, SGO Annual Meeting, Feb 2004.
O'Malley DM, Rutherford T, Kamsteeg M, Brown D, Schwartz P, Mor G. Phenoxodiol restores chemo-sensitivity in ovarian cancer. ASCO Annual Meeting, May-Jun 2003.
Mor G, Kamsteeg M, Sapi S, Shahabi S, Rutherford T. Phenoxodiol – an isoflavone analogue – induces apoptosis in chemo-resistant ovarian cancer cells. Society of Gynecological Oncologists Meeting, Feb 2003.
Mor G, Kamsteeg M, Sapi E, Shahabi S, Rutherford T. Phenoxodiol – an isoflavone analogue – induces apoptosis in chemo-resistant ovarian cancer cells. AACR Annual Meeting, Apr 2003.
Hutson TE, Mekhail T, Weiss P, Roman S, Dreicer R, Peereboom D, Olencki T, Kelly G, Ganapathi R, Bukowski R. Phase I study of Phenoxodiol given by constant intravenous infusion in patients with solid neoplasms refactory to standard therapy. AACR Annual Meeting, Apr 2002.
Liauw W, Links M, Pirabhahar S, Husband A, Kelly G, de Souza P. Phase I and pharmacokinetic study of weekly Phenoxodiol, a novel isoflav-3-ene, in patients with advanced, solid cancer. ASCO Annual Meeting, Oct 2001.